Skip to main content

Dexycu FDA Approval History

Last updated by Judith Stewart, BPharm on March 2, 2021.

FDA Approved: Yes (First approved February 9, 2018)
Brand name: Dexycu
Generic name: dexamethasone
Dosage form: Intraocular Suspension
Company: EyePoint Pharmaceuticals, Inc.
Treatment for: Postoperative Ocular Inflammation

Dexycu (dexamethasone) is a long-acting, injectable corticosteroid formulation administered intraocularly into the posterior chamber of the eye for the treatment of postoperative inflammation associated with cataract surgery.

Development timeline for Dexycu

Feb 12, 2018Approval Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery
Apr 13, 2017Icon Bioscience Submits NDA For Dexycu, a Potential Transformational Drug Therapy for Treating Inflammation Associated with Cataract Surgery

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.